These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30178256)

  • 21. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
    Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K
    PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
    Frydenlund N; Mahalingam M
    Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
    Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
    Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

  • 25. Epigenetic modulation in cancer immunotherapy.
    Gallagher SJ; Shklovskaya E; Hersey P
    Curr Opin Pharmacol; 2017 Aug; 35():48-56. PubMed ID: 28609681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?
    Ali MA; Matboli M; Tarek M; Reda M; Kamal KM; Nouh M; Ashry AM; El-Bab AF; Mesalam HA; Shafei AE; Abdel-Rahman O
    Immunotherapy; 2017 Jan; 9(1):99-108. PubMed ID: 28000527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy.
    Zhai Y; Wang J; Lang T; Kong Y; Rong R; Cai Y; Ran W; Xiong F; Zheng C; Wang Y; Yu Y; Zhu HH; Zhang P; Li Y
    Nat Nanotechnol; 2021 Nov; 16(11):1271-1280. PubMed ID: 34580467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetics meets immune checkpoints.
    Covre A; Coral S; Di Giacomo AM; Taverna P; Azab M; Maio M
    Semin Oncol; 2015 Jun; 42(3):506-13. PubMed ID: 25965370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
    Sepesi B; Nelson DB; Mitchell KG; Gibbons DL; Heymach JV; Vaporciyan AA; Swisher SG; Roszik J
    Ann Thorac Surg; 2018 Jun; 105(6):1621-1626. PubMed ID: 29510096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells.
    Medina Enríquez MM; Félix AJ; Ciudad CJ; Noé V
    PLoS One; 2018; 13(11):e0206818. PubMed ID: 30399174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Epigenetic Markers for Precision Medicine.
    Dumitrescu RG
    Methods Mol Biol; 2018; 1856():3-17. PubMed ID: 30178243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 35. Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumors.
    Bacolod MD; Barany F; Pilones K; Fisher PB; de Castro RJ
    Adv Cancer Res; 2019; 142():107-143. PubMed ID: 30885360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers of response to PD-1/PD-L1 inhibition.
    Maleki Vareki S; Garrigós C; Duran I
    Crit Rev Oncol Hematol; 2017 Aug; 116():116-124. PubMed ID: 28693793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
    Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
    Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
    Wang Q; Wu X
    Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic regulation and cancer (review).
    Chen QW; Zhu XY; Li YY; Meng ZQ
    Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
    Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
    Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.